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ABSTRACT
Objective: To evaluate the economic impact of a Bayesian
network model designed to predict clinical success of a new
chemical entity (NCE) based on pre-phase III data.
Methods: We trained our Bayesian network model on pub-
licly accessible data on 503 NCEs, stratiﬁed by therapeutic
class. We evaluated the sensitivity, speciﬁcity and accuracy of
our model on an independent data set of 18 NCE-indication
pairs, using prior probability data for the antineoplastic NCEs
within the training set. We performed Monte Carlo simula-
tions to evaluate the economic performance of our model
relative to reported pharmaceutical industry performance,
taking into account reported capitalized phase costs, cumula-
tive revenues for a postapproval period of 7 years, and the
range of possible false negative and true negative rates for
terminated NCEs within the pharmaceutical industry.
Results: Our model predicted outcomes on the independent
validation set of oncology agents with 78% accuracy (80%
sensitivity and 76% speciﬁcity). In comparison with the phar-
maceutical industry’s reported success rates, on average our
model signiﬁcantly reduced capitalized expenditures from
$727 million/successful NCE to $444 million/successful NCE
(P < 0.001), and signiﬁcantly improved revenues from $347
million/phase III trial to $507 million/phase III trial
(P < 0.001) during the ﬁrst 7 years post launch. These results
indicate that our model identiﬁed successful NCEs more efﬁ-
ciently than currently reported pharmaceutical industry
performances.
Conclusions: Accurate prediction of NCE outcomes is com-
putationally feasible, signiﬁcantly increasing the proportion
of successful NCEs, and likely eliminating ineffective and
unsafe NCEs.
Keywords: Bayesian network, Monte Carlo simulation, new
chemical entity, pharmacoeconomics, prediction.
Introduction
The estimated cost of developing a single new chemical
entity (NCE) into a successful therapeutic agent is
US$802 million (in year 2000 dollars, 95% conﬁdence
interval of $684–936 million) [1], with clinical phase
costs of $467 million, and taking into account “time
costs” related to the length of time from Investigational
New Drug (IND) approval to New Drug Application
(NDA) marketing approval, and the cost of capital.
Although the true cost of NCE development has gener-
ated debate [2–6], innovative drug development is
expensive by any measure. A substantial component of
this expense is related to the proportion of NCEs that
fail during the clinical trial development phase [7,8],
particularly those NCEs that fail during or after the
more costly later phases.
Over 60% of terminations occur later in the drug
development process, during phases II and III [9].
Because phase III studies generally require larger and
therefore more costly clinical trials, earlier termination
of even a fraction of late-phase failures gives rise to a
factoring of savings: terminating only 5% of all phase
III clinical failures in phase I would reduce out-of-
pocket clinical costs by 5.5–7.1% [10]. It is therefore
in the pharmaceutical industry’s interest to terminate
failures early, without compromising the quality of the
clinical trials or terminating successful agents, and
most importantly, without exposing clinical trial sub-
jects to unnecessary risk.
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We have constructed a Bayesian network model
[11,12] to calculate the probability that a speciﬁc NCE
will be clinically successful through phase III/NDA
approval given 1) prior data regarding success rates for
NCEs of the same therapeutic class (e.g., antineoplas-
tic, cardiovascular) and source (i.e., licensed in vs.
developed in-house, USA vs. non-USA); and 2) the
NCE’s pre-phase III toxicology and efﬁcacy data. The
aim of our model is to predict clinical success (safety
and efﬁcacy) for a speciﬁc NCE in question, given prior
data on NCEs in the same therapeutic class. To evalu-
ate our model’s performance, we compiled an indepen-
dent data set of oncology NCEs from several public
sources, and performed a Monte Carlo simulation,
sampling costs and revenues from reported pharmaco-
economic data distributions, to determine the eco-
nomic impact of our model relative to reported
pharmaceutical industry performances.
Methods
Sources of Data
Training data set. The data used to populate the con-
ditional probability tables for the Bayesian model
[11,12] were obtained from the Tufts Center for the
Study of Drug Development (TCSDD) sources [9]. The
TCSDD data included a total of 503 NCEs divided
more than 10 therapeutic classes, as deﬁned by the
TCSDD investigators, including Analgesic/Anesthetic
(49 NCEs), Antimicrobial (57 NCEs), Antineoplastic
(38 NCEs), Cardiovascular (120 NCEs), Central
Nervous System (110 NCEs), Endocrine (33 NCEs),
Gastrointestinal (15 NCEs), Immunologic (13 NCEs),
Respiratory (25 NCEs), and Miscellaneous (43 NCEs).
These data were descriptive only and did not include
information on individual NCEs.
Data on terminated NCEs. DiMasi [9] analyzed the
causes of failure for 348 NCEs that were withdrawn
from development. Nevertheless, NCEs that proceeded
through all clinical trial phases but failed to achieve
NDA approval are not included in DiMasi’s analysis,
and data on terminated NCEs were not stratiﬁed by
therapeutic class. Furthermore, DiMasi stratiﬁed by
“primary” cause of failure, thereby not disclosing any
degree of overlap, that is, NCEs that failed primarily
for one reason, but may have also failed for another
reason (e.g., an NCE that failed because it was not
safe, but was also not effective). The DiMasi analysis
demonstrated that of a total of 348 NCEs that were
terminated, the primary reason for termination was
efﬁcacy in 121, safety in 72, economics in 109, and
“other” in 46. Assuming that the proportions of causes
of failure are consistent across the withdrawn drugs,
we used these values to calculate an “overlap func-
tion” that accounts for the probability that a given
NCE will fail because of both safety and efﬁcacy con-
cerns [11,12].
Independent data set collection. We approached inves-
tigators at ﬁve pharmaceutical companies, requesting
from each de-identiﬁed data, including data on termi-
nated NCEs, to evaluate our model, but we were
unsuccessful in obtaining relevant data. Therefore, we
constructed an independent data set starting from a
collection of 213 published clinical trials previously
compiled from American Society of Clinical Oncology
(ASCO) abstracts of phase I NCEs [13]. We then
acquired outcome data (latest phase of development,
ongoing clinical trial activity, NDA approval, phase at
termination if relevant) for all antineoplastic NCEs
contained within the PharmaProjects database. We
determined which NCEs were common to both the
ASCO-derived database and the PharmaProjects data-
base. To acquire data regarding the characteristics of
these NCEs, we searched the National Center for Bio-
technology Information PubMed database for toxicity
and early-phase efﬁcacy data for each NCE-indication
pair (e.g., an NCE directed against a speciﬁc cancer
type). We were able to extract data for 18 NCE-
indication pairs, for which half were consistent across
data inputs in that all efﬁcacy studies for the given
NCE were performed on the same cancer type. The
remaining half of NCE-indication pairs was mixed,
with different cancer types studied across the in vitro,
in vivo, and phase I/II studies. For each NCE-
indication pair, the independent data set lists the
lowest reported therapeutic index for a vital organ, the
lowest reported therapeutic index for a disease-related
complication, and reported data on in vitro, in vivo,
and pre-phase III human efﬁcacy studies. When mul-
tiple studies were available, the earliest reported data
were used. We performed an additional search of
public sources to determine whether any NCEs listed
as “active” in our database have recently been
approved. This search resulted in changing one NCE
that was listed as “active phase III” in our database
to “marketed.” Half of the NCE-indication pairs
achieved either NDA approval or were still under
active investigation in phase III, whereas the remaining
half of NCE-indication pairs were either terminated at
or before phase III, or were active at a phase before
phase III.
Bayesian network model. A Bayesian Network (BN) is
a directed acyclic graph consisting of nodes (represent-
ing stochastic variables) and arrowed arcs (represent-
ing dependencies between the variables) [14,15]. A BN
has the capability of computing the probability that
the event represented by the top (root) node will occur,
given the data encoded within the lower (hidden) and
bottom (leaf) nodes. Data are entered for the leaf
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nodes, and Bayes theorem is used to “climb” up the
tree, to calculate the posterior probability of the root
node’s state given the data. We engineered a BN model
[11,12] encompassing the key variables in clinical drug
development (Fig. 1). Brieﬂy, our BN model [11,12]
computes the probability of clinical success for an
NCE, given the NCE’s characteristics (therapeutic
class, development source, i.e., in-licensed vs. in-house,
therapeutic indexes, and in vitro, in vivo, and clinical
data), in the context of prior data [1] on NCEs in the
same therapeutic class.
Implementation
We implemented the model in the Java 2 programming
language, within Apple Xcode on Apple OS X Tiger,
version 10.4.2 (Apple Inc., Cupertino, CA). An object-
oriented, model-view approach [16] was used to struc-
ture the program.
Model Evaluation
We had two prior probability models, one using a
pessimistic prior probability and one using an optimis-
tic prior probability. The rationale for using pessimistic
and optimistic prior probabilities is that the TCSDD
reports (from which we derived our conditional prob-
ability tables) provide the probability of failure based
on the current NCE failure rate, as well as the prob-
ability of failure assuming that all NCEs still under
development are successful (i.e., a more optimistic
probability of failure). Our pessimistic prior probabil-
ity model refers to the data that are based on the
current failure rate, whereas the optimistic prior prob-
ability model refers to the failure data that are based
on the assumption that all NCEs still under develop-
ment will not fail.
For each prior probability model we computed the
posterior probability of clinical success for each of the
18 NCE-indication pairs in our independent data set.
The NCE outcome deﬁnitions were structured to create
three sets of binary outcomes (success vs. failure). The
rationale for using three sets of binary outcomes is that
we aimed to assess our model in the setting of all
possible assumptions regarding the outcomes for NCEs
still under development. Therefore, we categorized our
outcome data in three ways: a) active phase III/
marketed vs. phase III terminated/pre-phase III, in
which an NCE is deemed successful if it is either still in
active phase III development or has received NDA
approval; b) marketed vs. not marketed, in which an
NCE is successful only if it has received NDA approval;
and c) optimistic, for which we assumed that all active
NCE development programs, regardless of latest phase
of activity, would result in NDA approval. Each binary
outcome deﬁnition classiﬁed all 18 NCEs as successful
or failed, resulting in three lists of outcomes for the 18
NCEs (one list for each outcome group). We used the
pessimistic prior probabilities to evaluate outcome
groups (a) and (b), and we used the optimistic posterior
probabilities to evaluate outcome group (c). We
recorded the resultant posterior probability expecta-
tions for each NCE-indication pair. We then plotted
receiver operating characteristic (ROC) curves, and
calculated the c-index [17] to determine the area under
the curve (AUC) for each ROC curve. We determined
the optimum sensitivity and speciﬁcity values for each
ROC curve.
Pharmacoeconomic Evaluation
We evaluated the economic impact the model would
have if used by drug development teams, given the
Figure 1 Bayesian network (BN) engineered
speciﬁcally to predict clinical success for a new
chemical entity (NCE). Shaded nodes represent
stochastic variables, and unshaded nodes repre-
sent input variables, which are fed data from
preclinical, phase I, and phase II studies for an
NCE under development.The BN computes the
probability of clinical success for the NCE in
question given prior data on 503 NCEs, strati-
ﬁed by therapeutic class.
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measured sensitivities and speciﬁcities of the three
outcome models on the independent data set, as well as
the sensitivity and speciﬁcity of the three outcome
models combined. Our goal was to compare our BN
model’s sensitivity and speciﬁcity values with the phar-
maceutical industry’s sensitivity and speciﬁcity values
by subjecting each model’s values to the Monte Carlo
simulation, sampling from reported distributions
for capitalized phase costs and cumulative 7-year
revenues.
We used reported pharmaceutical industry perfor-
mance data [1] to estimate the pharmaceutical indus-
try’s sensitivity and speciﬁcity for predicting success of
phase II NCEs through phase III to NDA approval as
follows: The probability that a phase II NCE will enter
phase III is 31.4% [1], and 68.5% of phase III NCEs
received NDA approval [1]. The proportion of true
positive (TP) NCEs (successful NCEs) is therefore
0.314 ¥ 0.685 = 0.215. The proportion of false posi-
tive (FP) NCEs (proceeded through phase III but failed
to get NDA approval) is 0.314 - 0.215 = 0.099. We
were unable to determine the pharmaceutical indus-
try’s true negative (TN) and false negative (FN) rates,
because it is impossible to determine what the fate of
terminated NCEs would have been. It is likely that a
proportion of terminated NCEs may have ultimately
proven to be successful. The rationale for including
TN and FN in our evaluation is that 1) TN and par-
ticularly FN have a signiﬁcant impact on NCE costs
and revenues because terminated would-be successful
NCEs result in development costs and lost potential
revenue; and 2) both TN and FN are required to
estimate the pharmaceutical industry’s sensitivities and
speciﬁcities for predicting NCE success. Therefore, we
computed the remaining proportion representing the
sum of the pharmaceutical industry’s TN and FN, as
1 - (TP + FP) = 0.686. We constructed a ﬂat distribu-
tion of the range from 0 to 0.686, with 5000 bins, to
include in the Monte Carlo simulation. We selected a
ﬂat distribution for the range of possible TN and FN
values for the pharmaceutical industry because there
are no data regarding the would-be outcomes of ter-
minated NCEs and we therefore did not want to bias
the simulation by emphasizing one or more regions of
the distribution. Each Monte Carlo simulation con-
sisted of 2000 cycles. Individual data values are
sampled from each distribution within each cycle of
the Monte Carlo simulation.
The overall goal of the Monte Carlo simulations is
to determine the expenditures and revenues for our BN
model and for the pharmaceutical industry, to permit
economically oriented comparisons. We submitted the
pharmaceutical model to the Monte Carlo simulation
three times to ensure the same number of simulation
cycles as performed for the three combined BN
outcome models. Each of the three pharmaceutical
industry models underwent two consecutive Monte
Carlo simulations. The role of the ﬁrst simulation was
solely to determine the sensitivity and speciﬁcity over
2000 cycles, sampling from the ﬂat distribution of FN
and TN in each simulation cycle, and computing each
cycle’s sensitivity (TP/[TP + FN]) and speciﬁcity (TN/
[TN + FP]). The second Monte Carlo simulation to
determine costs and revenues proceeded as for our BN
models, described below.
To express all monetary data in year 2000 dollars,
we used the current and real gross domestic product
(GDP) data [18] to calculate the GDP Implicit Price
Deﬂator, to deﬂate cost ﬁgures derived from data [19]
expressed in 1992 dollars. We used published data
[1,19] to set the cost ranges and distributions for the
Monte Carlo simulations. Capitalized phase costs [1]
used in the Monte Carlo simulation were (in millions
of year 2000 dollars) $30.5, $41.6, and $119.2, for
phase I, phase II, and phase III, respectively. Phase
costs were expressed as normal distributions, based on
the reported normal distribution of total capitalized
costs [1] (95% conﬁdence limits $684–936 million
around a mean of $802 million).
Revenue range for approved NCEs was estimated
from 7-year postapproval cumulative mean ($600
million) and top-decile ($3095 million) values [19].
The revenue parameter values were randomly sampled
from a gamma distribution, with a shape approximat-
ing the distribution of the reported return on invest-
ment for 18 pharmaceutical companies [19].
For each cycle of the Monte Carlo simulation, we
calculated the expenditures per successful virtual NCE,
and 7-year cumulative revenues per phase III trial
given the model’s submitted sensitivity and speciﬁcity
values. We performed Monte Carlo simulation, ran-
domly sampling from the reported cost and revenue
distributions. All distributions were divided into 5000
bins, and each Monte Carlo simulation ran for 2000
cycles. Identical simulation parameters were used to
evaluate each of the pairs of sensitivity and speciﬁcity
values for our BN model and for the pharmaceutical
industry performances.
Within each cycle of the Monte Carlo simulation,
expenditures per successful NCE, and 7-year cumula-
tive revenues per phase III trial were calculated given: 1)
the model’s sensitivity and speciﬁcity for predicting
clinical success; 2) the phase cost values randomly
sampled from the normally distributed cost distribu-
tions; and 3) the revenue value randomly sampled from
the gamma-distributed revenues. Each cycle used a
virtual group of 100 NCEs for which the submitted
model’s sensitivity and speciﬁcity values were used to
determine the proportion of the 100 virtual NCEs that
were accurately classiﬁed, which in turn permitted
expenditure and revenue calculations. We assigned the
virtual group of 100 NCEs an inherent success rate of
35% (i.e., 35 phase II NCEs would achieve NDA
approval in the virtual group of 100 NCEs). We set this
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inherent success rate to exceed reported success rates
for phase II NCEs [1] which is 0.215, the product of the
probability that a phase II NCE will enter phase III
(0.314) and the probability that a phase III NCE will
achieve NDA approval (0.685). The virtual group of
100 NCEs must have a success rate exceeding reported
pharmaceutical industry success rates to ensure that the
possibility of FN NCEs would be included in the simu-
lation. Changing the inherent success rate of the virtual
group of 100 NCEs had no impact on the resultant
differences between our BN model and the pharmaceu-
tical industry model.
Using the sensitivity and speciﬁcity values submitted
to the simulator, the proportion of TP, FP, TN, and FN
NCEs was calculated for the virtual group of 100
NCEs. The expenditure calculation summed the
sampled phase I and phase II costs for all 100 NCEs,
added the phase III costs for the proportion of NCEs
that the model correctly (TP) or incorrectly (FP) pre-
dicted to be successful, and divided the sum by TP to
yield the cost per successful NCE. The revenue calcu-
lation multiplied TP by the sampled 7-year revenue
value, and divided the product by the sum of TP and
FP (i.e., all phase II NCEs selected for phase III trials),
to yield the cumulative 7-year revenues per phase III
trial.
We compared expenditures and revenues between
our BN model and the pharmaceutical industry. We
used the t-test for normally distributed data (expendi-
tures) and the Mann–Whitney test for nonparametric
data (revenues). The Bonferroni correction factor was
applied to account for multiple tests. Monte Carlo
simulation was executed within the R programming
environment [20].
Results
Independent Data Set Characteristics
Publicly accessible pre-phase III data were accrued for
14 NCEs common to the ASCO and PharmaProjects
data sets, with 18 NCE-indication pairs, of which nine
were indication-consistent across in vitro, in vivo, and
early human studies, in that all study environments
were performed within the same indication. Latest-
phase analysis revealed that a total of six NCEs
received marketing approval. An additional two more
NCEs were active in phase III development. Two NCEs
were discontinued in phase III. Three NCEs were
active in phase II and one NCE was discontinued in
phase II.
Model Performance
Our BN model predicted the outcome on the indepen-
dent test set with an optimal accuracy of 78% (80%
sensitivity and 76% speciﬁcity). The sensitivities,
speciﬁcities, accuracies, and ROC AUC values for the
active phase III/marketed model, the marketed model,
the optimistic model, and the combined performance
of all three models are shown in Table 1. The ROC
curves are shown in Figure 2.
Pharmacoeconomic Evaluation
Our BN model signiﬁcantly reduced median expendi-
tures per successful NCE by $283 million below phar-
maceutical industry expenditures (39% reduction,
from $727 million to $444 million, P < 0.001, Fig. 3,
left). The BNmodel also signiﬁcantly increased median
cumulative 7-year revenues per phase III trial by $160
million above pharmaceutical industry revenues (46%
increase, from $347 million to $507 million,
P < 0.001, Fig. 3, right).
Comparisons of each of our BN’s three outcome
models individually against pharmaceutical industry
performance revealed similar trends across all of the
three outcome models (Table 2 and Fig. 4), with sig-
niﬁcant decreases in expenditures per successful NCEs
(Fig. 4, top), and increases in revenues per phase III
trial (Fig. 4, bottom).
Discussion
The impact of safety and toxicity on NCE failure is
signiﬁcant [9]. The cost of an NCE that will ultimately
fail is directly proportional to the length of time
between IND approval and termination of develop-
ment. It follows that earlier and accurate termination
of NCEs destined for failure results in: 1) signiﬁcant
development cost savings; 2) improved revenues
because of due to selective development of successful
NCEs; 3) freeing up clinical trial resources for other
more promising agents in the development pipeline;
and 4) limiting patient exposure to potentially unsafe
and/or ineffective investigational agents. Nevertheless,
Table 1 Bayesian network (BN) model performances for the three outcomes
Outcome Active phase III/marketed Marketed Optimistic Combined
Sensitivity (%) 89 67 75 80
Speciﬁcity (%) 89 83 64 76
Accuracy (%) 89 75 70 78
ROC AUC 0.83 0.61 0.68 0.72
AUC, area under the curve; ROC, receiver operating characteristic curve.
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overzealous termination of NCEs will impede the
development of novel effective therapies.
We have used publicly available data to construct
and independently validate a BN model of drug devel-
opment success. Based on our model’s overall perfor-
mance and economic impact, we have shown that
go/no-go decisions that take prior data into account
can result in signiﬁcant savings and improved rev-
enues. Terminating NCEs that would otherwise be
late-stage failures would not only prevent higher
expenditures but would also reduce exposing trial
subjects to unsafe and ineffective NCEs, and would
increase the proportion of pipeline NCEs that are ulti-
mately successful clinically and ﬁnancially. Ideally,
these added revenues would be translated into lower
pricing for brand name medications, thereby reducing
the cost burden on patients and third party payers.
We can infer from our ﬁndings that the pharmaceu-
tical industry’s accuracy for predicting late-phase
success is suboptimal. Even the modest predictive per-
formances of our BN’s marketed and optimistic
models improve on current pharmaceutical industry
performances. DiMasi et al. reported that, in compar-
ing year 2000 analyses [1] with prior analyses [8], a
smaller proportion of pharmaceutical industry failures
are occurring in phase III (12.6%, reduced from
17.1% reported in the earlier study). Nevertheless, a
reduction in NCE approvals ensued [21]. Taken
together, it is reasonable to hypothesize that the phar-
maceutical industry may have overcorrected for rising
development costs due to later-stage failures, and in so
doing has suppressed the development of novel thera-
pies. Our BN model has demonstrated the ability to
counter this trend, by increasing success-bound phase
III development activity, as evidenced by signiﬁcantly
increased revenue.
The main distinction between our model and pre-
viously described models is that our model focuses on
predicting the outcome of a speciﬁc NCE. Other
models [7–9,22–25] have taken a population-based
analysis approach, yielding valuable data on overall
success rates, but not truly addressing the termination
decision for a single, speciﬁc NCE. Other Bayesian
approaches described in the literature differ from our
approach with respect to the domain to which Bayes
theorem is applied. Published Bayesian approaches
Active phasa III/marketed outcome model Marketed outcome model
Optimistic outcome model Combined 3 outcome models
Se
ns
itiv
ity
Se
ns
itiv
ity
Se
ns
itiv
ity
Se
ns
itiv
ity
False positive rate(1 – specificity)False positive rate(1 – specificity)
False positive rate(1 – specificity)False positive rate(1 – specificity)
ROC AUC = 0.83 ROC AUC = 0.61
ROC AUC = 0.68 ROC AUC = 0.72
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
0.0 0.2 0.4 0.6 0.8 1.0
Figure 2 Receiver operating characteristic (ROC) curves for the Bayesian network models.AUC, area under the curve.
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within the ﬁeld of pharmaceutical development
compare the beneﬁts of Bayesian statistics over fre-
quentist approaches and focus on the utilization of
Bayesian statistics for the analysis of clinical trial data,
which are in turn used to deﬁne “stopping boundaries”
[26–29]. Berry et al. [27] used accumulated informa-
tion on an NCE’s performance to determine at which
point a given clinical trial’s evidence of efﬁcacy is suf-
ﬁciently negative that the trial should be discontinued,
but did not perform sensitivity analyses, and did not
address the issue of overall clinical success of the NCE.
Recently, De Ridder [30] described a simulation
approach to predict phase III outcomes based on phase
II data for a single agent, and reported beneﬁts with
respect to trial design and dosing issues for the ongoing
phase III trials of the drug in question. Nevertheless,
given that only a single drug was modeled, no valida-
tion studies, sensitivity analyses, or pharmacoeco-
nomic evaluation could be performed.
We acknowledge some limitations to our evalua-
tion, mainly as a result of our inability to access pro-
prietary data on terminated NCEs. We do not have
sufﬁcient data to evaluate NCE combinations, which
are particularly common in the oncology domain,
where monotherapy is rare. Similarly, we attempted to
acquire indication-speciﬁc data, although this require-
ment further limited our ability to ﬁnd complete data
for monotherapy NCEs, and we therefore included
some NCE data with “mixed” indications. Finding
complete indication-speciﬁc, publicly accessible data
for a given combination of NCEs was not possible.
Ideally, our input data would be indication-consistent
across all investigational environments, as well as con-
sistent with the latest-stage outcome data. We were
also further limited with respect to our outcome data,
in that when categorizing the outcomes by active phase
III/marketed, NCEs terminated in early phases are nec-
essarily categorized as having a bad outcome, when in
fact they may have been terminated appropriately.
Conversely, NCEs still active in early phases are also
categorized as having a bad outcome when the true
outcomes for these NCEs are not yet known. For these
reasons, we performed three evaluations to assess our
model’s performance assuming realistic (active phase
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Figure 3 Box plots demonstrating capitalized expenditures per successful NCE (left) and cumulative 7-year revenues per phase III trial (right) for the
pharmaceutical industry and our Bayesian network (BN) model (all three outcomes combined).
Table 2 Economic results for the pharmaceutical industry and the Bayesian Network (BN) models (median, interquartile range, in
millions of year 2000 US dollars)
Pharmaceutical
industry BN:All outcomes
BN: marketed/active
phase III BN: marketed BN: optimistic
Expenditures per successful NCE 727 (620–836) 444 (370–524) 379 (324–438) 458 (389–528) 506 (432–580)
Revenues per phase III trial 347 (267–579) 507 (343–804) 626 (468–1039) 436 (334–755) 404 (310–653)
P-value (vs. pharmaceutical industry) — P < 0.001 P < 0.001 P < 0.001 P < 0.001
NCE, new chemical entity.
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III/marketed), pessimistic (marketed only), and opti-
mistic (all active will be marketed) outcomes. Ongoing
efforts to construct mandatory clinical trial registries
will improve access to independent validation data.
Our independent data set may also be affected by
publication bias, in that it is possible that negative
studies are not published as frequently as promising
data, although these biases, should they exist, have no
bearing on the evaluation of our model. As well, our
validation data set was conﬁned to antineoplastic
NCEs, and we generalized the resultant sensitivity and
speciﬁcity values to determine pharmacoeconomic per-
formance. Improved access to proprietary data for
other therapeutic classes would be of interest for future
evaluations.
In summary, NCE R&D expenditures are report-
edly increasing, with a detrimental effect on the cost of
living of millions of Americans. Our BN approach is
novel in that individual NCE characteristics are
modeled on the background of prior data speciﬁc to
those same characteristics for similar NCEs. Despite
limited access to NCE development data, our model
demonstrated substantial improvement over reported
pharmaceutical industry performances. Open access to
proprietary, de-identiﬁed data from pharmaceutical
companies, particularly data on terminated NCEs,
would enhance our ability to further evaluate and opti-
mize the performance of our model.
The data on which we evaluate our model may not
be generalizable to pharmaceutical companies, but the
structure of the model is directly applicable to use a
given pharmaceutical or biotechnology company’s
stored data on previously failed compounds to
improve the accuracy of go/no-go decisions for NCE’s
in the pipeline. We have shown that the use of prior
data, perhaps even within-company data only, can
potentially improve the predicted results of NCE’s in
the pipeline substantially. We hope that our report will
encourage pharmaceutical companies to use their pro-
prietary data for the beneﬁt of their companies and for
society in the form of safer and more effective pipeline
drugs, and lower costs of development.
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